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Atrial fibrillation (AF) is the most common arrhythmia and among the leading causes of stroke and heart failure inWestern populations. Despite
the increasing size of clinical trials assessing the efficacy and safety of AF therapies, achieved outcomes have not always matched expectations.
Considering that AF is a symptom of many possible underlying diseases, clinical research for this arrhythmia should take into account their re-
spective pathophysiology. Accordingly, the definition of the study populations to be included should rely on the established as well as on the
new classifications of AF and take advantage from a differentiated look at the AF-electrocardiogram and from increasingly large spectrum of bio-
markers. Such an integrated approach could bring researchers and treating physicians one step closer to the ultimate vision of personalized
therapy, which, in this case, means anAF therapy based on refined diagnostic elements in accordancewith scientific evidence gathered from clin-
ical trials. By applying clear-cut patient inclusion criteria, future studies will be of smaller size and thus of lower cost. In addition, the findings from
such studies will be of greater predictive value at the individual patient level, allowing for pinpointed therapeutic decisions in daily practice.
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Introduction
Rene´ The´ophile Lae¨nnec’s message:
Rien n’est plus rare que l’exactitude de l’observation (Nothing is rarer
than the exactness of observation)
The present review shall sensitize the clinicians to the importance of
careful evaluation of the underlying causes of atrial fibrillation (AF) in
his patients with no apparent structural heart disease and remind the
scientific societies about the importance of accurate definition and
classification of this arrhythmia. Just as with the introduction of the
stethoscope,1 only preciseobservationwith careful reportingof find-
ings will build the fundamentals for sustained progress in diagnosis
and therapy.
With an increasing prevalence in themost recent studies, AF is the
most common arrhythmia and among the leading causes of stroke
and heart failure in Western populations,2 representing a heavy and
growing burden to society, patients, and health-care providers.
As discussed below, the increasing prevalence of AF with age is
likely due to accumulating predisposing factors and increasing myo-
cardial fibrosis, which also involves the atria. Taking a fatalistic view,
age being the only risk factor that cannot be controlled, any upstream
therapy will at best postpone the day of first AF occurrence. More-
over, AF risk prediction based on risk factors is supposedly less
accurate in older persons than in middle-aged adults, mirroring the
already well-known situation with regard to classical risk factors for
coronary artery disease,3 and confirmed by the fact that, so far,
no electrocardiogram (ECG) analysis study of P-wave or P–R
abnormalities has been conclusive with regard to predicting future
AF development.4
Thediagnosis ofAF is basedon typical ECGfindings. TherapyofAF
aims at controlling the ventricular rate (rate control) or at restoring
and maintaining sinus rhythm (rhythm control). Despite the fact that
the latter aspires to therapeutic perfection, many large studies have
failed to deliver convincing and reliable evidence that the effort was
worth the undertaking. Nevertheless, in these studies, sinus
rhythm was restored in some patients, suggesting that treatment
success may depend on adequate patient selection. Thus, improving
and refining the diagnosis of AF, beyond the definitions given in the
different guidelines, by linking it to theunderlying causes andmechan-
isms may be a promising approach for a more specific therapy.
Categorizing patients into carefully defined cohorts (classification)
will expectedly lead to smaller numbersof participants tobe included
in clinical trials for demonstrating therapeutic effects.
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The aim of the present review is to integrate classic dogmas of
AF, ranging from basic research to clinical experience, and to gener-
ate a philosophy for improving AF classification beyond its current
definitions.
Lessons learned from clinical
observations in atrial fibrillation
The first step for understanding a natural phenomenon is observa-
tion, followed by classification and nomenclature in a second step.
This fundamental rule to every science also applies to AF. All inter-
national guidelines for ‘idiopathic’ AF are still primarily based on
symptoms and time course, which, in the age of molecular biology,
does appear outdated and thus of questionable soundness.5,6
Table 1 shows the classifications of AF according to various para-
meters selected by different expert groups. While symptoms7 un-
doubtedly are the patient’s first reason of concern and the
physician’s first motivation for therapeutic action, they do not
favour logical pathophysiology-based reflection. Arrhythmic symp-
toms of AF do not correlate with underlying clinical risk, nor are
they indicators for treatment choice with regard to the long-term
therapeutic AF management strategy. Moreover, most episodes of
AF do remain clinically asymptomatic.8 The guidelines for the man-
agement of AFof the European Society of Cardiology adopted a clas-
sification based on the presentation and the time course of the
arrhythmia, thus assuming that all events will be symptomatic. Start-
ing from the first diagnosed episode, this classification distinguishes
between four possible time courses of AF: paroxysmal, persistent,
long-standing persistent, and permanent.5 This classification builds
on the concept that a progression continuumunderlies the evolution
of AF over time, paroxysmal episodes being progredient up to the
stage of permanent AF, as best summarized by the ‘AF begets AF’
dogma.
As it is generally accepted that only knowledge and understanding
about the cause of any disease will lead to successful therapy,9 we
must admit that neither of the two classifications outlined above ad-
equately describes pathophysiological entities qualifying as potential
targets for therapy. Yet, in many clinical studies, patients were exclu-
sively included basedon the presence of oneormoreof these clinical
symptoms and on the time course-dependent characteristics of
arrhythmia.
Recognizing that morbidity and mortality associated with AF had
remained unacceptably high despite all efforts aimed at improving
its management, the aetiology of AF was placed in the foreground
for the first time by the Third Consensus Conference of the Atrial
Fibrillation Competence Network/European Heart Rhythm Associ-
ation (AFNET/EHRA).10 This major change in attitude was based on
well-defined clinical, pathophysiological, and genetic characteristics.
Furthermore, the need for taking into consideration coincident or fa-
cilitating factors associatedwith but not necessarily causally linked to
AF was also stressed for the first time.
An aetiology-based definition of AF could represent the first step
towards categorizing AF according to the primary or dominant
underlying disorders. Such an approach would then contribute to
improving our understanding about why a given atrium is in fibrilla-
tion and to defining sound pathophysiology-based therapeutic
targets. The following underlying primary disorders were already
proposed: inherited AF, monogenic forms, polygenic forms, focal
AF, and post-operative AF.10 These different forms of AF are repre-
sentative of specific causes requiring specific therapies at the individ-
ual patient level. Neither vagal11 or sympathetic forms of AF nor
subclinical aspects of atrial inflammation or fibrosis were yet consid-
ered. By consistently following this type of approach, the term of
‘idiopathic’ AF would ultimately disappear and be replaced by indi-
vidual nosological entities.
Lessons learned from
electrophysiological observations
in atrial fibrillation
The coincidence of two elements, the trigger and the substrate, is at
the origin of AF, whereby the trigger reflects an initiating mechanism
that can be perpetuated within the substrate. While the trigger
sounds like a sudden event, the substrate reflects an evolutionary
modification of the electrophysiological properties of the atrial
myocardium.
Rapid electrical discharges, for example, originating from the pul-
monary veins, are a prototypical trigger.12 Many other potential
triggers, such as but not limited to acute stress of the atrial wall and
vagal and/or sympathetic activity, have been much less in the focus
of discussion.
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Table 1 Synopsis of symptom, time course, and pathophysiology-based classifications of atrial fibrillation according
to references 6,7,10
EHRA symptom score ESC first episode classification AFNET/EHRA pathophysiology-based types
EHRA I No symptom Paroxysmal ,48 h Inheritable monogenetic
EHRA II Mild symptoms
Activity not affected
Persistent .7 days Inheritable polygenetic
EHRA III Severe symptoms
Activity affected
Long standing, persistent .1 year Focal
EHRA IV Disabling symptoms Permanent Accepted Complex
Post-operative
EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology; AFNET, Atrial Fibrillation Competence Network.
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The ‘substrate’ reflects the concept according to which the trig-
gered electrical activation perpetuates in an autonomous way. For
this to happen, the stable conduction properties of the atrial tissue
need being disturbed. This may occur in a large spectrum of acute,
progressive, or permanent pathologies ranging from macroscopic
tissue infiltration to molecular abnormalities as encountered in
primary genetic or genetically facilitated predispositions.
In a critically unstable atrial tissue, focal activity may arise spontan-
eously, leading thereby to initiating or sustaining fibrillation. On the
other hand, the trigger itself can modify the substrate, especially if
active for a prolonged period. In the classic experiments of Allessie
and co-workers13 in goats, AF induced by rapid atrial pacing
became sustained over time, as a response to increasing degrees of
tissue remodelling. This model mimics the clinical observation of
rapidly firing pulmonary vein foci which entrain the atrial tissue and
inwhich, as a proof of concept, trigger eliminationby radio-frequency
ablation cures the arrhythmia.14
It is conceivable and even likely that other mechanisms contribute
to substrate remodelling prior to fibrillation, such as chronic atrial
wall stretch,15 chronic inflammation,16 autonomic nervous system
activity,11 and fibrosis,17,18 to cite but a few.
While coronary artery disease was typically not considered a
direct causal factor of AF, left ventricular ischaemia does promote
atrial wall stress as confirmed by recent observations which
showed that patients originally diagnosed with idiopathic AF more
often suffer from insidious coronary artery disease than healthy con-
trols in sinus rhythm.19 In addition to thesemacro-electrophysiological
considerations, new insights into substrate conditioning can be
expected from ongoing basic research in genetics, proteomics, and
metabolomics. All these considerations expectedly will contribute
to the integrational classification of AF proposed in Table 2.
Atrial fibrillation is also characterized by its time course, as sug-
gested in the ESC guidelines. In fact, little is known about the intrinsic
evolution of AF over time which opens the field for longitudinal
follow-ups of laboratory and anatomical parameters. Remembering
that even so-called stable AF does still exhibit dynamic aspects,20
long-term ECG monitoring, including by the means of implantable
recorders, may contribute to understand better the trigger and sub-
strate interaction.
Repetitive activation was identified as a consequence of re-entry
in 1906. Since then, advances in the field paralleled the technical
progress of electrophysiological measurements, resulting in the
description of multiple re-entry circuits, meandering wavelets,
and spiral waves. New horizons were reached with more sophis-
ticated mapping analysis in animal models21 and in silico computer-
modelling algorithms, allowing for 3D assessment and simulation
of AF.22
Lessons learned from
electrocardiographic observations
in atrial fibrillation
Atrial fibrillation can only be diagnosed by electrocardiography, the
absence of P-waves, the presence of fibrillatory waves with a cycle
length usually ,200 ms, and ‘absolutely’ irregular R–R intervals
being the mandatory features. In this respect, it is surprising that
the F-waves’ morphology has not deserved further attention
despite the ancient observation showing that coarse waves were
rather a sign of recent onset AF, while fine oscillations were rather
in favour of longstanding AF.23 Such typical characteristics of ECGs
in AF have not been considered potentially relevant for rendering
more precise the clinical definition of AF in current international
guidelines.5,6 However, it is highly likely that fibrillation of different
origins or at different stages of progression, i.e. in different substrates,
might manifest with different fingerprints in the ECG tracing. While
the application of modern signal processing technologies applied to
the ECG had been proposed a long time ago, it is only recently that
measurements based on spatial, temporal, and frequency ECG ana-
lyses or using other non-linear methods such as spatial (vector) ele-
ments andQRSTwaves suppression have shownpromising results.24
For the time being, these methods remain essentially focused on the
discrimination between paroxysmal and persistent AF, assessing the
duration of AF. However, they could represent automatic methods
for discriminating between persistent and permanent AF through
simple surface ECG analysis. Such information could become highly
relevant in clinical settings, for patient management as well as for
guiding therapeutic decisions, with recent developments sketching
the first lines for use in daily practice.25 Overall, in carefully defined
AF patient populations, such ECG ‘blow-up’ technologies (Figure 1)
are very promising and may become a new cornerstone for the
classification of AF.25
The development of a simple and cheap diagnostic and classifica-
tion tool, which should be readily usable by primary care physicians
in their daily practice,might contribute to aetiology-based therapeut-
ic decision-making, help identifying patients expected to benefitmost
fromrhythmcontrol therapy, guide treatment choice (cardioversion,
ablation, or drug therapy), and contribute to predict treatment
outcome, ideally at the individual patient level. Based on its value
for understanding the pathophysiology of AF, its contribution for
reconstructing the history of AF in a single patient, and its expected
strong contribution for treatment decisions at the individual
patient level, it is foreseeable that advanced ECG analysis should
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Table 2 Compilation of published and newelements in
view of an integrational classification of atrial fibrillation
Factor Reference base Class
Symptom EHRA I–IV
Time ESC Hours/years
Pathophysiology AFNET Type
Electrocardiogram Advanced signal analysis To be tested
Biomarkers and
genetics
From C-reactive protein
to mRNA
To be developed
Associated risk
factors
From hypertension to
CAD
To be defined per
patient
These elements should be part of a diagnostic ‘work up’ for patients with atrial
fibrillation and no primarily identified structural heart disease. Patients with similar
factors define the future groups for clinical studies.
EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology;
AFNET, Atrial Fibrillation Competence Network; mRNA, messenger RNA; CAD,
coronary artery disease.
A new look at atrial fibrillation 2741
become a key element in AF characterization and be included as such
in future classifications of AF.26
Lessons learned from atrial
fibrillation therapy
General considerations
According the AFNET/EHRA Consensus,10 therapeutic efforts
against AF must cover four key areas. (i) Factors that increase the
risk for AFmust be identified and treated in the sense of an upstream
therapy aimed at protecting the substrate. (ii) In line with first
attempts of a pathophysiology-based classification of AF, arrhythmo-
genic processes have tobe identified and specific therapies have tobe
applied. (iii) The relevanceofAFdurationhas to be studied in cohorts
in order to identify a disease stage in which rhythm control will be
considered inappropriate. (iv) Therapies aimed at preventing compli-
cationsofAF, such as heart failure and thrombo-embolic events, have
to be implemented in parallel to the rhythmological efforts.
As wise as these recommendations are and as obvious as they may
seem in retrospect, they are lacking the necessary base of solid clinical
evidence,mainly due to the fact that clinical trials published to date did
not includeor stratify patients basedon thenewly suggested yet logical
principles for AF classification. In the most recent update of the
American College of Cardiology Foundation/American Heart Associ-
ation Task Force on Practice Guidelines/Heart Rhythm Society
(ACCF/AHA/HRS) focused on the management of patients with AF,
13mega-trials investigating the clinical benefits of different therapeutic
interventions were reviewed.6 Although more than 25 000 patients
were included in these trials, none was overwhelmingly conclusive,
with statistical significances scattered across some groups or sub-
groups of patients. Such statistically significant differences between
themeanvaluesof two groupsmaynot necessarily be relevant for clin-
ical decision-making. Furthermore, when applied to individual patients
seen in daily practice, the clinical relevance of such statistical significant
differences betweenmean valuesmaybe additionally hamperedby the
fact that the inclusion criteria used for these AF therapy trials did not
rely on a specific AF classification beyond the duration of AF and, in
some cases, the anatomical size of the atria.
Last but not least, one should remember that anti-arrhythmic drug
research has long been the exclusive domain of pharmacologistswho
generally did not interact with clinicians. As a result, the first classifi-
cation of (direct) anti-arrhythmic drugs was based on the observed
modifications of the cellular action potentials (Vaughan Williams
classes I– IV).27 Subsequently, ion channel-related properties were
added, assuming (or possibly hoping) that what happened in the
cells would also happen in patients. The results of the Cardiac Ar-
rhythmia Suppression Study (CAST) initiated the fall of drug
Figure1 Spectral envelopes (SE) of atrial activity computed on pairs of electrocardiogram leads (V5 and V6) in patients with persistent and long-
standing persistent atrial fibrillation, and corresponding multidimensional organization index (MOI) and multidimensional spectral entropy (MSE)
demonstrating organization decrease from persistent to long-standing persistent atrial fibrillation (modified from Uldry et al.25).
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therapyof arrhythmias, basedon theobservation that in patients pre-
senting with ectopic ventricular beats within 2 years after an acute
myocardial infarction, a recognized risk factor for sudden cardiac
death, the effective suppression of ectopic ventricular beats with fle-
cainide led to significant excess mortality.28 However, as shown in
later studies, flecainide only caused harm in the setting of ischaemia
and/orcardiac structural abnormalities anddidnot increasemortality
whenused for the treatmentof supraventricular arrhythmias in struc-
turally normal hearts.29 The lesson taught is that the use of any drug,
including anti-arrhythmics, bears a potential for harm and that careful
patient selection is required to fully exploit the potential for cure.
Anti-arrhythmic drugs and atrial
fibrillation
For the practical purpose of this review, the following will focus on
rhythmcontrol only, i.e. on pharmacological cardioversion andmain-
tenance of sinus rhythm. While the treatment of precipitating or re-
versible causes of AF before initiating anti-arrhythmic drug therapy is
generally recommended as a measure of good cardiology practice,
this recommendation has not been prospectively evaluated in ad-
equately designed endpoint trials and therefore deserved a C level
of evidence in the latest ACCF/AHA/HRS guideline update.6
Pharmacological cardioversion can be safely and efficiently
achieved with various currently available anti-arrhythmic agents,30
whereby the reportedly high efficacy may in fact be related to the
usually well-selected patient populations (with permanent and per-
sistent forms of AF being consistently excluded). Interestingly,
the exact mechanism(s) by which anti-arrhythmic drugs can stop
AF, as well as the mechanism(s) by which AF may spontaneously
resolve, remain unclear. While drugs tend to decrease conduction
velocity leading to a sudden (within seconds to minutes) decrease
of the number of wavelets, accelerations with wave collisions
have also been described, both mechanisms ultimately leading to
wavelet extinction.
Maintenance of sinus rhythm after cardioversion is a much more
complex issue. In this setting, feared or factual drug toxicity domi-
nates clinical decision-making. After the CAST study,28 class I anti-
arrhythmic drugs were considered too dangerous, especially for
patients with impaired ventricular function. The publication of the
Atrial Fibrillation Follow-up Investigation of Rhythm Management
(AFFIRM) study results,31 which showed in the intention-to-treat
analysis that rhythm control offered no survival advantage over
rate control, further reduced the enthusiasm for pharmacological
anti-arrhythmic therapy. However, a retrospective on-treatment
analysis of the same study showed that patients who were in sinus
rhythm had a better prognosis.32 The class III anti-arrhythmic drug
amiodarone was poorly tolerated in a significant number of patients
and the QT interval prolongation nourished the fear of torsades de
pointes. Thus, the next step was to shift all hopes towards an
amiodarone-like drug without its side effects, an ambitious thought
if one considers, following Galen’s principle, that only a poison can
cure! Many large clinical endpoint trials were conducted with drone-
darone, the conflicting results of which were recently carefully
reviewed and discussed by Le Heuzey.33 Thus, the same lesson was
repeatedly taught: careful patient selection is the way to go to
obtain meaningful clinical study results relevant to daily practice.
Overall, the following key messages can be derived from many
(patient-) years of observation in clinical trials: (i) anti-arrhythmic
drugs can be very effective when given to well-selected patients;
(ii) acute effects of a drug do not necessarily translate into long-term
positive results30; and (iii) considering thatAF is onlyone symptomof
many possible underlying diseases, improving this symptom cannot
be expected to cure the disease. Thus, future studies should use
very stringent patient inclusion criteria derived from a sound
pathophysiology-based integrational AF classification. As important
spin-offs, heterogeneous responses will be prevented and smaller
sized trials with improved relevance to daily clinical practice will be
conducted.
Electric therapy of atrial fibrillation
External cardioversion (EC), with its 50 years of practice, is still the
gold standard for restoring sinus rhythm.34 External cardioversion
is easy to perform, cheap, close to 100% effective, and exposes the
patient to a low embolic risk if performed ,48 h after the onset of
AF or appropriate anticoagulation.5 Maintenance of sinus rhythm
after successful EC may reveal more challenging, with a potentially
high AF recurrence rate. The latter can be lowered by (i) careful diag-
nosticworkupofprecipitating factors, including sports, variousdrugs,
family history, and metabolic or vascular disorders, followed by (ii)
prescription of the appropriate therapy, be it cause related or
simply anti-arrhythmic or both.
Internal cardioversionofAFwas shown tobe a possible alternative
to EC,35 leading to the development of an implantable ‘atrioverter’
(InControl)which reliably recognizedAFand immediately converted
96% of the AF episodes into sinus rhythm, but had a 20% recurrence
rate within 1 min.36 As the reader will easily recognize by now, the
recurrence rate was of course not a problem of the device but
rather of the substrate. Furthermore, the delivery of discharges of
1–3 J was considered uncomfortable for the patient and the study
was too small and too short to show that ‘sinus rhythm begets
sinus rhythm’. However, it is conceptually possible that, with appro-
priate electrode positioning, well-defined stimulation sequences,
and/or adapted low energy discharges, an intelligent implantable
rhythm control device exerting no harm to, or even protecting,
atrial tissue could be developed.37 Under these premises, it would
become possible to investigate whether, and if so under which cir-
cumstances, reverse atrial remodelling could happen, e.g. depending
upon the prior duration of AF. Such intelligent electric therapies have
several obvious advantages, among which their high specificity
related to their immediate action at the arrhythmic tissue level,
their capability to repeat and adapt the intervention, and the simple
intervention required for implantation. Tachycardia overdrive or
programmed stimulation had been used in the past to stop atrial
re-entry tachycardias with reasonable success.38 Although the
proof of principle was delivered in single cases, the overall results
were not satisfactory. Nevertheless, electric rhythm control could
become an interesting adjunct to other anti-arrhythmic therapies.
Starting from these initial cardioverting observations, the concept
was broadened to preventing AF. One hypothesis was that regular
pacemaker stimulation might suppress ectopic activity and thereby
override trigger events. In fact, many pacemakers and implantable
defibrillators include pacing algorithms developed for the prevention
or termination of AF. Randomized clinical trials have demonstrated
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that atrial-based pacing, compared with single-chamber ventricular
pacing, reduced the incidence of AF, most notably in patients with
the sick sinus syndrome.39 This effect may be due to primary electric
stabilization, to the prevention of retrograde conduction through
ventricular pacing, or to the reduction of intra-atrial pressure by
A-V synchrony. More recently, specific atrial pacing strategies for
preventing AF have been made available, which adapt the atrial
pacing rate in response to atrial premature beats or following
exercise in order to achieve continuous atrial overdrive pacing
(CAOP).40 These CAOP strategies have yielded promising but
inconsistent results in several prospective trials,41 possibly due
again to differences in patient selection criteria and/or pacing algo-
rithms. Finally, in ASSERT (Asymptomatic Atrial Fibrillation and
Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation
Reduction Atrial Pacing Trial), CAOP did not prevent the develop-
ment of AF in hypertensive patients at risk for AF and with no
history of documented AF.42
These observations confirm that, while certain pacing strategies
can be highly effective in carefully selected pathologies, they may
fail in broadenedpatientpopulationswhicharemore likely toencom-
pass multiple aetiologies of AF.
Ablation therapy of atrial fibrillation
The basic concept of surgical ablation of AFwas the compartmental-
ization of the atrial tissue into areas small enough for preventing
re-entry circuits to occur.43 According to this concept, put into prac-
tice with the Maze procedure, the cutting lines would forbid propa-
gation of the activation beyond them and therefore make it
impossible for the substrate to fibrillate. Developed in 1987, with
some adjustments of the cutting-line patterns and with improved
instruments since then, this procedure remains the gold standard
of surgical therapy of AF. With a success rate exceeding 90% in
many centres, this procedure is applied whenever a patient with AF
presents with an indication for open heart surgery.44
Catheter ablation mimics the Maze procedure without the need
for open heart surgery. The search for continuous refinement of
this approach is reflected in the discussions on appropriate
mapping techniques as well as in the multitude of ablation instru-
ments which are in use or under investigation, ranging from heat to
cold application,45 all sharing the common promise of generating
continuous and transmural lines blocking electrical conduction.
Large surveys have been conducted which included patients with
all types of AF but only minimal information is available regarding
‘hits on target’. Controlled clinical studies showed favourable out-
comes, the most sensitive drawback of catheter ablation being the
frequent need for reintervention.46 The high recurrence rate (includ-
ing a high rate of silently recurring AF), the lack of documentation of
long-termhaemodynamic benefits, and the paucity of available cost–
benefit data remain of concern. While following best intentioned
guidelines,47 the amount of totally destroyed substrate (atrial
tissue) that results from an estimated annual number of procedures
exceeding 300 000 worldwide certainly justifies a more in-depth re-
flection onmore personalized procedures. As an example, the initial
design of the ablation lines with a cutting length exceeding 30 cm43
has never been substantially questioned, although optimization
could be attempted based on computer simulation approaches
(Figure 2).48 As cutting, burning, or freezing atrial tissue results in
the destruction of atrial tissue, the question is not whether larger
areas of destruction will deliver better results but whether equally
good results could be achieved with more tissue being preserved.
Furthermore, even if the definition of the ablation lines is clear, exe-
cuting them in the individual patient remains a challenge, such that
simplified procedures may result in improved feasibility. Further po-
tential targets for ablation deserving more thoughts have been
described, namely spots with continuous electrical activity
(CFAE).49 The pathophysiological context of CFAEs, ranging from
zones of extremely slow conduction to zones of vagal nerve
endings, and the definition of these spots in terms of time, shape,
and size still represent major hurdles. It is therefore not surprising
that, even in the unfortunate absence of a unanimously accepted def-
inition of recurrence, the ablation of CFAEs alone (i.e. without pul-
monary vein isolation) resulted in an 80% recurrence rate of AF in
the Substrate and TriggerAblation for Reduction ofAtrial Fibrillation
(STAR AF) trial.50
The latter developments are in clear contrast to the scientific ap-
proach followed by Haissaguerre et al.,12,14 who exactly observed
(possibly remembering Lae¨nnec!), reported, anddefinedone specific
form of ectopic electric activity initiating episodes of paroxysmal fib-
rillation originating from the pulmonary veins.Only thereafter, radio-
frequency ablation of this well-defined region was performed. This
scientifically sound approach, in which intervention follows observa-
tion, curedAF in95%of thepatientspresentingwith thesepredefined
characteristics. In patients with other causes of AF, extended pul-
monary vein isolation can be reconciled with the Cox approach, i.e.
with a partial compartmentalizationof atrial tissue.Ongoing progress
regarding online anatomic imaging, atrial electrical activity mapping,
and applied ‘coagulation’ areavisualizationmake it reasonable to con-
ceive that, in a not-all-too-far future, computer-based simulations in-
tegrating anatomical and electrocardiographic informationwill allow
for designing individualized ideal ablation patterns prior to interven-
tion, just as an aeroplane pilot adapts his flight plan to the weather
chart.
Conclusions and outlook:
integrating observations made
in atrial fibrillation
With this review, a more detailed diagnostic differentiation of AF
before engaging into treatment is advocated. As multiple patho-
physiological processes precede and coincide with this form of ar-
rhythmia, the integration of all known classification aspects of AF
together with the use of selected biomarkers and a careful ECG ana-
lysis may contribute to a more individualized classification. The early
identification of pro-fibrillatory conditions will allow for the imple-
mentation of preventive measures and upstream therapies. Specific
clinical constellations have to be identified as early as possible to
allow for a cause-related cure and for the identification of patients
with a definitively unstable substrate amenable only to care for pre-
venting complications. This should finally permit personalized
therapy at its best scientific, clinical, and cost-effective level. Adhering
to this vision requires that future studies will be conducted in such
carefully classified populations in which the clinical, pathophysio-
logical, time course, electrocardiographic, and biomarker-related
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aspects of AF will all be integrated, as proposed in Table 2. This
concept was further elaborated in a new AFNET/EHRA consensus
document.51 Studies that will be conducted in this setting will be of
smaller size, lower cost, and higher clinical relevance to the treating
physicians. Should they fail, we might not have exactly followed
Lae¨nnec’s advice.
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